Apyx Medical Corp Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Apyx Medical Corp (APYX) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.50% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-10.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-03-10
- Apyx Medical Corp share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2024-03-31 was 4.20%.
- Apyx Medical Corp share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2025 was 4.50%, a 7.14% increase from fiscal 2024.
- Apyx Medical Corp share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.20%, a 2.33% decline from fiscal 2023.
- Apyx Medical Corp share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.30%, a 10.26% increase from fiscal 2022.
- Apyx Medical Corp share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 3.90%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | 4.50% 10-K · filed 2026-03-10 | ||||
| 2025-09-30 | 4.50% 10-Q · filed 2025-11-06 | ||||
| 2024-12-31 | 4.20% 10-K · filed 2026-03-10 | ||||
| 2024-09-30 | 4.20% 10-Q · filed 2024-11-08 | ||||
| 2024-06-30 | 4.20% 10-Q · filed 2024-08-08 | ||||
| 2024-03-31 | 4.20% 10-Q · filed 2024-05-09 | ||||
| 2023-12-31 | 4.30% 10-K · filed 2025-03-13 | ||||
| 2023-09-30 | 4.30% 10-Q · filed 2023-11-09 | ||||
| 2022-12-31 | 3.90% 10-K · filed 2024-03-21 | ||||
| 2013-12-31 | 0.60% 10-K/A · filed 2014-05-08 | ||||
| 2013-06-30 | 0.40% 10-Q/A · filed 2013-09-25 | ||||
| 2012-12-31 | 0.40% 10-K/A · filed 2014-05-08 | 2.60% 10-K · filed 2013-04-01 | |||
| 2011-12-31 | 2.60% 10-K/A · filed 2014-05-08 | 2.27% 10-K · filed 2013-04-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Microbot Medical Inc. (MBOT) | $0.089B | -7.97 | |
| KORU Medical Systems, Inc. (KRMD) | United States | $0.151B | -106.78 |
| LENSAR, Inc. (LNSR) | United States | $0.087B | 2.02 |
| SkinHealth Systems Inc. (SKIN) | United States | $0.086B | -3.17 |
| Pulmonx Corp (LUNG) | United States | $0.082B | -1.16 |
| RenovoRx, Inc. (RNXT) | United States | $0.076B | -3.62 |
| FRACTYL HEALTH, INC. (GUTS) | United States | $0.075B | -1.18 |
| Lucid Diagnostics Inc. (LUCD) | United States | $0.170B | |
| CVRx, Inc. (CVRX) | United States | $0.067B | -2.62 |
| DarioHealth Corp. (DRIO) | $0.066B | -1.39 |